Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice

Translational Stroke Research

Volumn 3, Issue 3, 2012, Pages 381-389

  Leung, Philberta Y ^a,b   Hurst, Sawan ^a   Berny Lang, Michelle A ^a   Verbout, Norah G ^a,b   Gailani, David ^d   Tucker, Erik I ^a,b   Wang, Ruikang K ^c   McCarty, Owen J T ^a,e   Gruber, András ^a,e  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b Traffic Technology Solutions   (United States)

^c University of Washington   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Factor XI; Hemostasis; Ischemia; Neuroprotection; Thrombolysis

Indexed keywords

14 E 11; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; FIBRIN; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; HEMOSTASIS; INTERNAL CAROTID ARTERY; MALE; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIMATE; PRIORITY JOURNAL; REPERFUSION; REPERFUSION INJURY; SINGLE DRUG DOSE; THROMBOSIS;

EID: 84865794214     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0186-5     Document Type: Article

References (33)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123: e18-e209.
2. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA. Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Eng J Med. 2001; 344: 395-402.
3. Newman MF, Mathew JP, Grocott HP, Mackensen GB, Monk T, Welsh-Bohmer KA, Blumenthal JA, Laskowitz DT, Mark DB. Central nervous system injury associated with cardiac surgery. Lancet. 2006; 368: 694-703.
4. Suri MF, Yamagishi K, Aleksic N, Hannan PJ, Folsom AR. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis. 2010; 29: 497-502.
5. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008; 111: 4113-7.
6. Gruber A, Hanson SR. Factor XI-dependence of surface-and tissue factor-initiated thrombus propagation in primates. Blood. 2003; 102: 953-5.
7. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006; 203: 513-8.
8. Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol. 2009; 29: 1986-8.
9. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost. 2007; 5: 1106-12.
10. Renne T, Oschatz C, Seifert S, Muller F, Antovic J, Karlman M, Benz PM. Factor XI deficiency in animal models. J Thromb Haemost. 2009; 7 Suppl 1: 79-83.
11. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009; 7 Suppl 1: 84-7.
12. Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. Thromb Res. 2011; 128: e62-6.
13. Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Active tissue factor and activated XI in patients with acute ischemic cerebrovascular events. Eur J Clin Invest. 2012; 42(2): 123-9.
14. Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009; 113: 936-44.
15. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renne T, Gruber A, Gailani D. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010; 116: 3981-9.
16. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274: 1017-25.
17. Kilic E, Hermann DM, Hossmann KA. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport. 1999; 10: 107-11.
18. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998; 3: 257-60.
19. Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther. 1998; 20(Suppl B): B18-41.
20. Pfeilschifter W, Spitzer D, Czech-Zechmeister B, Steinmetz H, Foerch C. Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice. Stroke. 2011; 42(4): 1116-21.
21. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011; 32(16): 1968-76.
22. Berny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A. Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke. 2011; 42(6): 1736-41.
23. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. 2005; 2(3): 396-409.
24. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci. 2011; 31: 8456-63.
25. Abrams PJ, Emerson CR. Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy. 2009; 29: 167-81.
26. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost. 2002; 87: 774-6.
27. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005; 3: 695-702.
28. Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009; 114: 452-8.
29. Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol. 2007; 570: 167-74.
30. Zhang H, Lowenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010; 116: 4684-92.
31. Yamashita A, Nishihira K, Kitazawa T, Yoshihashi K, Soeda T, Esaki K, Imamura T, Hattori K, Asada Y. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost. 2006; 4: 1496-501.
32. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998; 101(1): 10-4.
33. Meijers JC. Feedback controversy stops here. Blood. 2009; 114: 235.